Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
25
08
2020
accepted:
25
11
2020
revised:
23
11
2020
pubmed:
19
12
2020
medline:
28
9
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Invasive ductal carcinoma (IDC) is often accompanied by ductal carcinoma in situ (DCIS). Whether the DCIS component affects the 21-gene recurrence score (RS) is unclear. Consecutive ER-positive, HER2-negative, N0-1 patients with RS results were included. Patients were divided into pure IDC and IDC with DCIS (IDC/DCIS) groups. The RS, the expression of its 16 cancer genes and prognosis were compared between IDC and IDC/DCIS patients. A total of 1458 patients were enrolled, 320 of whom had concomitant DCIS. DCIS component was independently associated with lower RS (P = 0.038). IDC/DCIS patients more often had a low-risk RS (P = 0.018) or intermediate-risk RS (P = 0.024). Regarding individual genes in the RS panel, Ki67, CCNB1 and MYBL2 in the proliferation group and MMP11 and CTSL2 in the invasion group were significantly lower among IDC/DCIS patients than pure IDC patients. Among IDC/DCIS patients, lower RS was independently correlated with a higher DCIS proportion and lower DCIS grade. Within a median follow-up of 31 months, the DCIS component in IDC did not significantly influence prognosis. IDC with DCIS component is associated with a lower 21-gene RS, possibly due to lower expression of proliferation and invasion genes. DCIS proportion and grade independently influenced the 21-gene RS in IDC/DCIS patients. Due to the relatively short follow-up period and low recurrence rate, the impact of the DCIS component in IDC on prognosis needs further evaluation.
Sections du résumé
BACKGROUND
Invasive ductal carcinoma (IDC) is often accompanied by ductal carcinoma in situ (DCIS). Whether the DCIS component affects the 21-gene recurrence score (RS) is unclear.
METHODS
Consecutive ER-positive, HER2-negative, N0-1 patients with RS results were included. Patients were divided into pure IDC and IDC with DCIS (IDC/DCIS) groups. The RS, the expression of its 16 cancer genes and prognosis were compared between IDC and IDC/DCIS patients.
RESULTS
A total of 1458 patients were enrolled, 320 of whom had concomitant DCIS. DCIS component was independently associated with lower RS (P = 0.038). IDC/DCIS patients more often had a low-risk RS (P = 0.018) or intermediate-risk RS (P = 0.024). Regarding individual genes in the RS panel, Ki67, CCNB1 and MYBL2 in the proliferation group and MMP11 and CTSL2 in the invasion group were significantly lower among IDC/DCIS patients than pure IDC patients. Among IDC/DCIS patients, lower RS was independently correlated with a higher DCIS proportion and lower DCIS grade. Within a median follow-up of 31 months, the DCIS component in IDC did not significantly influence prognosis.
CONCLUSIONS
IDC with DCIS component is associated with a lower 21-gene RS, possibly due to lower expression of proliferation and invasion genes. DCIS proportion and grade independently influenced the 21-gene RS in IDC/DCIS patients. Due to the relatively short follow-up period and low recurrence rate, the impact of the DCIS component in IDC on prognosis needs further evaluation.
Identifiants
pubmed: 33335279
doi: 10.1038/s41416-020-01212-w
pii: 10.1038/s41416-020-01212-w
pmc: PMC7921681
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-981Références
Kuerer, H. M., Albarracin, C. T., Yang, W. T., Cardiff, R. D., Brewster, A. M., Symmans, W. F. et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J. Clin. Oncol. 27, 279–288 (2009).
doi: 10.1200/JCO.2008.18.3103
Espina, V. & Liotta, L. A. What is the malignant nature of human ductal carcinoma in situ? Nat. Rev. Cancer 11, 68–75 (2011).
doi: 10.1038/nrc2950
Holland, R., Connolly, J. L., Gelman, R., Mravunac, M., Hendriks, J. H., Verbeek, A. L. et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J. Clin. Oncol. 8, 113–118 (1990).
doi: 10.1200/JCO.1990.8.1.113
Chagpar, A. B., McMasters, K. M., Sahoo, S. & Edwards, M. J. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? Surgery 146, 561–567 (2009).
doi: 10.1016/j.surg.2009.06.039
Logullo, A. F., Godoy, A. B., Mourao-Neto, M., Simpson, A. J., Nishimoto, I. N. & Brentani, M. M. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. Braz. J. Med. Biol. Res. = Rev. brasileira de. Pesqui. medicas e biologicas 35, 913–919 (2002).
doi: 10.1590/S0100-879X2002000800008
Goh, C. W., Wu, J., Ding, S., Lin, C., Chen, X., Huang, O. et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J. Cancer Res. Clin. Oncol. 145, 1877–1886 (2019).
doi: 10.1007/s00432-019-02930-2
Dieterich, M., Hartwig, F., Stubert, J., Klocking, S., Kundt, G., Stengel, B. et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Breast 23, 346–351 (2014).
doi: 10.1016/j.breast.2014.01.015
Wong, H., Lau, S., Yau, T., Cheung, P. & Epstein, R. J. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br. J. Cancer 102, 1391–1396 (2010).
doi: 10.1038/sj.bjc.6605655
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
doi: 10.1056/NEJMoa041588
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).
doi: 10.1200/JCO.2005.04.7985
Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721–728 (2008).
doi: 10.1200/JCO.2007.15.1068
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65 (2010).
doi: 10.1016/S1470-2045(09)70314-6
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B. & Senn, H. J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319–1329 (2009).
doi: 10.1093/annonc/mdp322
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206–2223 (2013).
doi: 10.1093/annonc/mdt303
Wu, J., Fang, Y., Lin, L., Fei, X., Gao, W., Zhu, S. et al. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget 8, 38706–38716 (2017).
doi: 10.18632/oncotarget.16313
Gourgou-Bourgade, S., Cameron, D., Poortmans, P., Asselain, B., Azria, D., Cardoso, F. et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in cancer trials). Ann. Oncol. 26, 2505–2506 (2015).
doi: 10.1093/annonc/mdv478
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005–2014 (2015).
doi: 10.1056/NEJMoa1510764
Lee, M. H., Han, W., Lee, J. E., Kim, K. S., Park, H., Kim, J. et al. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res. Treat. 47, 208–214 (2015).
doi: 10.4143/crt.2013.223
Solin, L. J., Gray, R., Baehner, F. L., Butler, S. M., Hughes, L. L., Yoshizawa, C. et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 105, 701–710 (2013).
doi: 10.1093/jnci/djt067
Toss, M., Miligy, I., Gorringe, K., Mittal, K., Aneja, R., Ellis, I. et al. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. J. Clin. Pathol. 73, 76–82 (2020).
doi: 10.1136/jclinpath-2019-205939
Gonzalez, L. O., Junquera, S., del Casar, J. M., Gonzalez, L., Marin, L., Gonzalez-Reyes, S. et al. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Hum. Pathol. 41, 980–989 (2010).
doi: 10.1016/j.humpath.2009.08.027
Eiro, N., Cid, S., Fernandez, B., Fraile, M., Cernea, A., Sanchez, R. et al. MMP11 expression in intratumoral inflammatory cells in breast cancer. Histopathology 75, 916–930 (2019).
doi: 10.1111/his.13956
Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E. & O’Higgins, N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252–257 (2000).
doi: 10.1186/bcr65
de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V., Dekker-Ensink, N. G. et al. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 175, 605–615 (2019).
doi: 10.1007/s10549-019-05195-y
Kim, J.-Y., Han, W., Moon, H.-G., Park, I.-A., Ahn, S. K., Kim, J. et al. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Clin. breast cancer 13, 385–391 (2013).
doi: 10.1016/j.clbc.2013.04.005
Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C. et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 19, 2263–2271 (2001).
doi: 10.1200/JCO.2001.19.8.2263
Wu, S. G., Zhang, W. W., Sun, J. Y. & He, Z. Y. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance. Epidemiol., End. Results Database Anal. Cancer Manag. Res. 10, 527–534 (2018).
Rakovitch, E., Nofech-Mozes, S., Hanna, W., Baehner, F. L., Saskin, R., Butler, S. M. et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res. Treat. 152, 389–398 (2015).
doi: 10.1007/s10549-015-3464-6